Sexually transmitted infections (STIs) remain a major public health concern worldwide. Despite advances in screening, diagnosis, and treatment, millions of new infections occur every year. In the United States alone, more than 2.5 million cases of chlamydia, gonorrhoea, and syphilis were reported in 2022. Many infections remain undiagnosed because they cause few or no symptoms, allowing them to progress silently and potentially cause long-term complications.
One of the most serious consequences of untreated sexually transmitted infections is infertility. Research has consistently shown that infections such as chlamydia and gonorrhoea can damage the reproductive tract, leading to pelvic inflammatory disease (PID), tubal scarring, and difficulties becoming pregnant. Recent clinical updates published in 2024 have highlighted new screening recommendations and diagnostic approaches aimed at reducing the burden of STI-related complications.
The Growing Burden of Sexually Transmitted Infections
Sexually transmitted infections affect people of all ages, but young adults and sexually active individuals remain at the highest risk. While some infections cause noticeable symptoms such as discharge, pain, sores, or bleeding, many women experience no symptoms at all.
This silent nature is particularly concerning because untreated infections can ascend from the lower genital tract into the uterus, fallopian tubes, and ovaries. Once this occurs, inflammation can damage delicate reproductive tissues, increasing the risk of chronic pelvic pain, ectopic pregnancy, miscarriage, and infertility.
The most commonly reported bacterial STIs include:
- Chlamydia (Chlamydia trachomatis)
- Gonorrhoea (Neisseria gonorrhoeae)
- Syphilis (Treponema pallidum)
Other sexually transmitted organisms receiving increasing attention include:
- Mycoplasma genitalium
- Trichomonas vaginalis
- Herpes simplex virus
- Mpox (formerly monkeypox)
Clinicians are now recognising that infections beyond the traditional STI pathogens may also contribute to reproductive tract disease and infertility.
Chlamydia: The Silent Threat to Fertility
Among all sexually transmitted infections, chlamydia is considered one of the most significant causes of preventable infertility.
Chlamydia often causes no symptoms, particularly in women. As a result, many infections remain untreated for months or even years. During this time, the bacteria may travel from the cervix into the upper reproductive tract, causing inflammation and scarring.
The fallopian tubes are particularly vulnerable. Damage to these structures can block the passage of eggs from the ovaries to the uterus, resulting in tubal factor infertility. In some cases, partial blockage increases the risk of ectopic pregnancy, a potentially life-threatening condition where a pregnancy develops outside the uterus.
Research suggests that a substantial proportion of tubal infertility cases can be traced back to previous chlamydial infections. However, determining exactly how many cases are attributable to chlamydia remains challenging because many women never receive a diagnosis during the acute infection phase.
Researchers have explored the use of blood tests that detect antibodies against chlamydia. These tests can provide evidence of previous infection, even years later. Although current serological tests are not perfect, they offer valuable insights into the long-term impact of chlamydia on fertility and may help improve future estimates of infertility caused by this infection.
Gonorrhoea and Reproductive Health
Like chlamydia, gonorrhoea can infect the cervix, urethra, rectum, and throat. Untreated gonorrhoea may also ascend into the upper reproductive tract and trigger pelvic inflammatory disease.
The inflammation associated with gonorrhoea can cause scarring of the fallopian tubes and surrounding tissues. Repeated infections increase the likelihood of permanent reproductive damage.
One of the challenges facing healthcare providers is the growing problem of antibiotic resistance in gonorrhoea. Over time, the bacterium has developed resistance to multiple antibiotic classes, making treatment more complex.
Current treatment recommendations have been updated to address resistance patterns and ensure effective management. Prompt diagnosis and treatment remain essential for preventing complications and reducing transmission.
Pelvic Inflammatory Disease: A Major Cause of Infertility
Pelvic inflammatory disease is one of the most important links between sexually transmitted infections and infertility.
PID occurs when bacteria spread from the lower genital tract into the uterus, fallopian tubes, or ovaries. Symptoms may include:
- Lower abdominal pain
- Fever
- Pain during intercourse
- Abnormal vaginal discharge
- Irregular bleeding
However, some women experience only mild symptoms or none at all.
Each episode of PID increases the risk of future infertility. Even a single episode can cause lasting damage to the fallopian tubes. Repeated infections significantly increase the likelihood of infertility and chronic pelvic pain.
The best strategy for preventing PID remains early detection and treatment of sexually transmitted infections before they have the opportunity to spread.
New Screening Recommendations for Syphilis
Syphilis has experienced a concerning resurgence in many countries, prompting updated screening recommendations.
Recent clinical guidance now emphasises broader screening efforts, particularly in communities with elevated syphilis rates. High community prevalence is defined as a primary or secondary syphilis case rate greater than 4.6 cases per 100,000 people.
One of the most significant updates involves pregnancy care. The American College of Obstetricians and Gynecologists now recommends universal syphilis screening three times during pregnancy:
- At the first prenatal visit
- During the third trimester
- At delivery
These recommendations apply regardless of individual risk factors.
The rationale is clear. Untreated maternal syphilis can lead to miscarriage, stillbirth, neonatal infection, and severe congenital complications. Early identification and treatment dramatically reduce these risks.
Extragenital Screening: Looking Beyond Traditional Testing
Historically, STI testing focused primarily on genital samples. However, growing evidence suggests that infections frequently occur at other body sites.
New clinical guidance encourages consideration of extragenital testing for gonorrhoea and chlamydia, particularly in women with relevant exposure histories.
Potential testing sites include:
- The throat (pharynx)
- The rectum (anus)
Extragenital infections are often asymptomatic and may be missed if only genital testing is performed. Identifying these hidden infections can improve treatment outcomes and help reduce ongoing transmission.
Healthcare providers are increasingly encouraged to take comprehensive sexual histories and consider testing based on individual risk factors rather than relying solely on traditional screening approaches.
Emerging Concerns: Mycoplasma genitalium and Trichomoniasis
While chlamydia and gonorrhoea remain the best-established STI-related causes of infertility, researchers are increasingly investigating other pathogens.
Mycoplasma genitalium has gained attention as a potential contributor to reproductive tract inflammation and PID. Although evidence is still evolving, studies suggest this organism may play a role in infertility and adverse reproductive outcomes.
Trichomonas vaginalis is another infection under investigation. Traditionally associated with vaginal irritation and discharge, it may also contribute to reproductive tract inflammation and increase susceptibility to other sexually transmitted infections.
More research is needed to fully understand the impact of these organisms on fertility and long-term reproductive health.
Protecting Fertility Through Prevention
The encouraging news is that many cases of STI-related infertility are preventable.
Effective prevention strategies include:
- Regular sexual health screening
- Prompt treatment of diagnosed infections
- Partner notification and treatment
- Consistent condom use
- Routine healthcare visits
- Open discussions with healthcare providers about sexual health
Young women and individuals with new or multiple sexual partners should be particularly proactive about screening, even when no symptoms are present.
Healthcare providers also play a critical role by following updated screening recommendations and ensuring patients receive appropriate testing and follow-up care.
Conclusion
Sexually transmitted infections continue to represent a significant threat to reproductive health worldwide. Chlamydia and gonorrhoea remain leading causes of pelvic inflammatory disease and tubal factor infertility, while emerging evidence suggests that organisms such as Mycoplasma genitalium and Trichomonas vaginalis may also contribute to reproductive complications.
Recent clinical updates have expanded recommendations for syphilis screening, enhanced consideration of extragenital testing, and refined approaches to diagnosis and treatment. These changes reflect a growing understanding of how sexually transmitted infections affect long-term health outcomes.
The strongest defence against STI-related infertility remains prevention, early detection, and timely treatment. By staying informed and engaging in regular sexual health screening, women can significantly reduce their risk of reproductive complications and protect their future fertility.
References
Hufstetler K, Llata E, Miele K, Quilter LAS. Clinical Updates in Sexually Transmitted Infections, 2024. Journal of Women’s Health. 2024;33(6):827-837.
Tsevat DG, Wiesenfeld HC, Parks C, Peipert JF. Sexually transmitted diseases and infertility. American Journal of Obstetrics and Gynecology. 2017;216(1):1-9.
Horner PJ, Anyalechi GE, Geisler WM. What Can Serology Tell Us About the Burden of Infertility in Women Caused by Chlamydia? Journal of Infectious Diseases. 2021;224(Suppl 2):S80-S85.



